Skip to main content

Deciphex

Category: AI in Healthcare

Deciphex is a developer of AI-powered digital pathology software designed to accelerate pathological analysis. Deciphex was founded in 2017. The company is led by Donal O'Shea. Based in Dublin, Ireland. Team size: 101-500. Total funding raised: $84.96M. Latest round: Venture Debt. Key investors include ACT Venture Capital, SV Health Investors, Charles River Laboratories, Novartis, Molten Ventures, Claret Capital Partners.

Founded
2017
Headquarters
Dublin, Ireland
Team size
101-500
Total funding
$84.96M

Value proposition

To accelerate drug development and improve diagnostic accuracy by providing AI-powered tools that enhance the speed and efficiency of pathology workflows.

Products and solutions

Patholytix, Diagnexia, Diagnexia Analytix

Unique value

Deciphex combines AI-powered image analysis with a global network of expert pathologists, providing on-demand access to specialized expertise for both preclinical and clinical pathology.

Target customer

Pharmaceutical companies, contract research organizations (CROs), and diagnostic laboratories.

Industries served

Pharmaceuticals, Biotechnology, Healthcare

Technology advantage

The company's platform leverages deep learning algorithms to automate the analysis of tissue samples, significantly reducing turnaround times and improving the accuracy of results. Their business model also includes a service component, connecting clients with a network of subspecialty pathologists for remote consultations.

How they differentiate

Deciphex differentiates itself by offering solutions across both preclinical research and clinical diagnostics. Their platform, Patholytix, is designed for toxicologic pathology in a research setting, while Diagnexia is a clinical platform that connects laboratories with a global network of subspecialty pathologists for remote consultations. This dual focus, combined with their use of AI to accelerate workflows and a service-based model that provides access to expertise, sets them apart from competitors who may focus more narrowly on either clinical or research applications.

Main competitors

PathAI, Proscia, Paige

Key partnerships

Novartis, Charles River Laboratories, Aga Khan University Hospital

Notable customers

Charles River Laboratories (also an investor and strategic partner), Aiforia (strategic partnership to distribute AI models), Novartis, Major pharmaceutical and contract research organizations (CROs), NHS Trusts (UK)

Major milestones

Launch of Patholytix, a digital pathology workflow and AI platform for preclinical research., Launch of Diagnexia, the world's first online clinical pathology department, providing on-demand access to remote subspecialty pathologists., Successful closure of multiple significant funding rounds, including a Series B and a recent venture debt facility to fuel expansion., Expansion of services into the US, UK, Canadian, and Middle Eastern markets., Received CE-IVD certification for its Diagnexia platform., Launch of Diagnexia Analytix (Jan 2025), AI-driven pathology services for translational R&D., Diagnexia achieved full UKAS accreditation (ISO 15189:2022) for Oxford Histopathology Laboratory (Nov 2025)., Charles River and Deciphex extended global partnership for digital pathology (Feb 2025).

Growth metrics

Specific growth metrics such as revenue or user numbers are not publicly disclosed.

Market positioning

Deciphex is positioned as a significant innovator in the digital pathology market. It is recognized for its specialized focus on AI-powered solutions that enhance the productivity of pathologists in both research and clinical environments. The company is scaling rapidly, aiming to become a global leader in on-demand access to pathology expertise.

Geographic focus

Deciphex is headquartered in Dublin, Ireland, with a strong initial focus on the European market. However, with recent funding, it is actively expanding its global footprint, particularly in North America (USA and Canada), the UK, and the Middle East.

Patents and IP

Information not publicly available.

About Donal O'Shea

Donal O'Shea is a serial entrepreneur with over 20 years of experience in life sciences, diagnostics, and technology. He has founded multiple technology start-ups, including the digital pathology software company Slidepath, which was successfully acquired by Leica Biosystems. His expertise lies in leveraging technology to innovate within the life sciences and diagnostics sectors.

Official website: